Data Year:

For its 2025 fiscal year, GERON CORP, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
John A. Scarlett M.D.
Former Chairman of the Board, President and Chief Executive Officer
Total Compensation $7,422,754 View details Pay Rank By Title In Biotechnology industry #166 View more
Andrew J. Grethlein Ph.D.
Former Executive Vice President, Chief Operating Officer
Total Compensation $3,316,444 View details Pay Rank By Title In Biotechnology industry #55 View more
Dawn C. Bir
Former Interim President and Chief Executive Officer
Total Compensation $522,122 View details Pay Rank By Title In Biotechnology industry #754 View more
Michelle J. Robertson
Executive Vice President, Finance, Chief Financial Officer, Treasurer and Interim Secretary
Total Compensation $2,250,082 View details Pay Rank By Title In Biotechnology industry #198 View more
Joseph Eid M.D.
Executive Vice President, Research & Development, Chief Medical Officer
Total Compensation $1,001,052 View details Pay Rank By Title In Biotechnology industry #158 View more
James Ziegler
Former Executive Vice President, Chief Commercial Officer
Total Compensation $2,392,709 View details Pay Rank By Title In Biotechnology industry #103 View more
Harout Semerjian
President and Chief Executive Officer
Total Compensation $10,221,755 View details Pay Rank By Title In Biotechnology industry #107 View more
Ahmed ElNawawi
Executive Vice President, Chief Commercial Officer
Total Compensation $2,881,334 View details Pay Rank By Title In Biotechnology industry #95 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at GERON CORP as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. GERON CORP income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. GERON CORP annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
John A. Scarlett M.D.
Former Chairman of the Board, President and Chief Executive Officer
Total Cash $309,781 Equity $5,386,404 Other $1,726,569 $7,422,754
Andrew J. Grethlein Ph.D.
Former Executive Vice President, Chief Operating Officer
Total Cash $563,276 Equity $1,842,453 Other $910,715 $3,316,444
Dawn C. Bir
Former Interim President and Chief Executive Officer
Total Cash $318,190 Equity $163,674 Other $40,258 $522,122
Michelle J. Robertson
Executive Vice President, Finance, Chief Financial Officer, Treasurer and Interim Secretary
Total Cash $799,100 Equity $1,439,530 Other $11,452 $2,250,082
Joseph Eid M.D.
Executive Vice President, Research & Development, Chief Medical Officer
Total Cash $989,600 Equity $0 Other $11,452 $1,001,052
James Ziegler
Former Executive Vice President, Chief Commercial Officer
Total Cash $470,028 Equity $1,161,619 Other $761,062 $2,392,709
Harout Semerjian
President and Chief Executive Officer
Total Cash $524,538 Equity $9,695,400 Other $1,817 $10,221,755
Ahmed ElNawawi
Executive Vice President, Chief Commercial Officer
Total Cash $307,692 Equity $2,573,400 Other $242 $2,881,334
For its 2025 fiscal year, GERON CORP, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Harout Semerjian CEO Pay $11,008,126 Median Employee Pay $314,826 CEO Pay Ratio 35:1
For its 2024 fiscal year, GERON CORP, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Dawn Bir Total Cash $583,314
Elizabeth O'Farrell Total Cash $630,749
Gaurav Aggarwal, M.D. Total Cash $589,843
John McDonald Total Cash $588,249
Robert Spiegel Total Cash $583,321
Susan Molineaux Total Cash $582,471
V. Bryan Lawlis Total Cash $586,656
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.